FCHI8,141.92-0.19%
GDAXI24,083.53-0.19%
DJI49,167.79-0.13%
XLE57.000.41%
STOXX50E5,860.32-0.39%
XLF51.80-0.02%
FTSE10,321.09-0.56%
IXIC24,887.100.20%
RUT2,788.190.04%
GSPC7,173.910.12%
Temp27.1°C
UV0.3
Feels29.4°C
Humidity71%
Wind10.4 km/h
Air QualityAQI 1
Cloud Cover20%
Rain0%
Sunrise06:00 AM
Sunset06:47 PM
Time6:55 PM
Cayman Journal
27 April 2026
Sign In
Markets13FInsidersPress ReleasesCompaniesPeopleReal EstateYachtAI Agents + MCPBusinessEconomyMarkets & FinanceTechnology
DEF 14ASEC Filing

TREACE MEDICAL CONCEPTS, INC. — DEF 14A Filing

TMCI
April 6, 2026 at 12:00 AM

🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Treace Medical Concepts, Inc. (TMCI). It's an official invitation and information packet for the company's 2026 Annual Meeting of Stockholders. Think of it as the agenda and briefing materials for a big company vote.

👉 In simple terms: If you own stock in Treace, this document tells you what you're voting on, who's running the company, and how much its leaders get paid. The meeting is virtual on May 19, 2026.

🏢 What The Company Does

Treace Medical Concepts is a medical device company. They focus on foot and ankle surgery, specifically pioneering a system called the Adductoplast® for correcting bunions. They aim to improve surgical outcomes and recovery times.

👉 In simple terms: They make specialized tools and implants that help surgeons fix bunions more effectively. It's a niche player in the large orthopedic device market.

🗳️ The Proposals You're Voting On

Stockholders will vote on three main items. The board recommends voting FOR on all of them.

  1. Proposal 1: Elect Three Directors. You're voting to re-elect Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan to the board. If elected, their terms will expire in 2029.
  2. Proposal 2: Advisory Vote on Executive Pay. This is a non-binding "say-on-pay" vote where you can voice your opinion on the compensation for top executives like the CEO.
  3. Proposal 3: Ratify the Auditor. This is a standard vote to approve the accounting firm Grant Thornton LLP as the company's independent auditor for 2026.

👉 Why it matters: Your vote directly influences the company's leadership and oversight. The director election shapes the board's strategic direction, and the pay vote, while advisory, signals shareholder sentiment to the company.

👥 Meet the Board & Leaders

The board is split into three classes with staggered terms. Here are the people up for election and key figures:

  • Lance A. Berry (Age 53): CFO/COO of Artivion. Former CFO of Wright Medical. Brings deep financial and medical device operational experience.
  • Elizabeth "Betsy" S. Hanna (Age 61): President of Cyted Health. Former CEO of Clinical Genomics. Expert in commercializing medical products.
  • Jane E. Kiernan (Age 65): CEO of Surgimatix. Former CEO of Salter Labs. Strong leadership and board experience in medical devices.
  • John T. Treace (CEO & Chair): The founder of the company (2014). Has over 20 years in the foot & ankle device industry. His combined CEO/Chair role is supported by a lead independent director.

The board is mostly independent (6 out of 7 directors). It has three key committees: Audit, Compensation, and Nominating & Corporate Governance.

💼 How Executives Get Paid (Compensation)

The proxy details the 2025 pay for top executives. Here’s a simplified look at the Summary Compensation Table figures:

  • John T. Treace (CEO): Total compensation was $1.63 million in 2025. The largest portion ($1.05M) was from stock awards, aligning his pay with company performance.
  • James R. (J.R.) Sprague (CFO): Total compensation was $902,000 in 2025, with a significant portion also in stock and option awards.
  • Scot M. Elder (Chief Legal Officer): Total compensation was $786,000 in 2025.

👉 Why it matters: The pay mix is heavily weighted toward equity (stocks/options), which is common for growth companies. This structure is meant to incentivize executives to grow the company's value over the long term.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

  • Founder-Led: CEO John Treace has deep industry expertise and vision.
  • Focused Strategy: Dedicated to a specific, high-need area (bunion surgery).
  • Governance: Maintains independent board oversight and standard committees.

⚠️ Risks & Considerations:

  • Market Adoption: Success depends on surgeons and hospitals adopting their specialized system.
  • Competition: Faces larger, established orthopedic device companies.
  • Classified Board: The staggered board structure (where only part of the board is up for election each year) can make it harder for shareholders to enact quick changes.

🧠 The Analogy

This proxy statement is like the annual report card and agenda for a school's parent-teacher association (PTA) meeting. You, as a "parent" (shareholder), get to review the "teachers" (executives), see their "pay" (compensation), and vote on the "PTA board members" (directors) who will oversee the "school's" (company's) direction for the next few years.

🧩 Final Takeaway

Treace Medical is holding its annual shareholder meeting to re-elect its board and approve its auditor. The key takeaway is that the company is stable and continuing its focused strategy under founder leadership. Your vote, especially on the director nominees, endorses the current strategic path and governance of this niche medical device firm.